Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 6/20 | 0.44 |
| ▸ | AR | P10275 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826448 | 0.83 | HTT (0.47) | PLA2G7ARALDH1A1 | |
| SCHEMBL826431 | 0.83 | SLC22A12 (0.39) | PLA2G7ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL826758 | 0.81 | KDM4E (0.46) | PLA2G7ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL826861 | 0.79 | BRAF (0.60) | BRAFKDR | |
| SCHEMBL6814419 | 0.77 | ABCC9 (0.46) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL2088279 | 0.77 | PDK1 (0.41) | ALDH1A1 | |
| SCHEMBL28689163 | 0.77 | AR (0.61) | PLA2G7ARSLC22A12 | |
| SCHEMBL826801 | 0.76 | BRAF (0.56) | BRAFKDR | |
| SCHEMBL28932082 | 0.72 | AR (0.65) | AR | |
| SCHEMBL5154044 | 0.72 | PLA2G7 (0.49) | PLA2G7KDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053630-B | Benzothiazole derivative and application thereof | 中国人民解放军第二军医大学 | 2022-04-01 | — | — | CN | disclosed |
| EP-2358689-B9 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2016-08-03 | — | — | EP | disclosed |
| EP-2358689-B1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| EP-2358689-A1 | Benzothiazole derivatives as anticancer agents | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| WO-2010064722-A1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | PLA2G7 3243/4885AR 1103/4885KDM4E 1956/4885 |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | PLA2G7 3243/4885AR 1103/4885KDM4E 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.